Bank of America’s Lucid Diagnostics LUCD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$102K Buy
88,527
+18,212
+26% +$23.2K ﹤0.01% 5512
2025
Q4
$76.6K Buy
70,315
+29,652
+73% +$33.2K ﹤0.01% 5700
2025
Q3
$41.1K Buy
40,663
+11,917
+41% +$13K ﹤0.01% 6896
2025
Q2
$33.1K Sell
28,746
-14,151
-33% -$18.3K ﹤0.01% 6929
2025
Q1
$63.9K Buy
42,897
+42,707
+22,477% +$51.2K ﹤0.01% 6672
2024
Q4
$156 Buy
190
+42
+28% +$37 ﹤0.01% 7644
2024
Q3
$121 Sell
148
-26
-15% -$21 ﹤0.01% 7679
2024
Q2
$143 Buy
174
+171
+5,700% +$145 ﹤0.01% 7632
2024
Q1
$3 Sell
3
-11
-79% -$14 ﹤0.01% 7618
2023
Q4
$20 Sell
14
-160
-92% -$211 ﹤0.01% 7652
2023
Q3
$204 Buy
+174
New +$252 ﹤0.01% 7406
2023
Q1
Sell
-18
Closed -$24 8077
2022
Q4
$24 Buy
+18
New +$32 ﹤0.01% 7946
2022
Q3
Sell
-1,450
Closed -$3K 8043
2022
Q2
$3K Sell
1,450
-4,006
-73% -$8.9K ﹤0.01% 7713
2022
Q1
$18K Buy
5,456
+74
+1% +$270 ﹤0.01% 7559
2021
Q4
$29K Buy
+5,382
New +$43.7K ﹤0.01% 7409

Other funds holding LUCD

Bank of America's LUCD Position: Q1 2026 in Review

Bank of America increased its Lucid Diagnostics (LUCD) stake by 26% in Q1 2026, buying an estimated $23.2K and bringing the position to 88,527 shares worth $102K. The position accounts for ﹤0.01% of the portfolio, ranked #5512.

Bank of America first reported a position in LUCD in Q4 2021 and has held it in 15 quarters since. 103 funds tracked by Wall St. Rank hold LUCD as of Q1 2026.

  • Bank of America held 88,527 shares of Lucid Diagnostics worth $102K as of Q1 2026.
  • Bank of America bought 18,212 Lucid Diagnostics shares in Q1 2026, an estimated $23.2K.
  • Lucid Diagnostics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #5512 holding.
  • Bank of America first reported a position in Lucid Diagnostics in Q4 2021 and has held it in 15 quarters since.
  • 103 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.